Danny Zanardo - Anteris Technologies Commercial International
AMEUF Stock | USD 6.50 0.43 7.08% |
Executive
Mr. Danny Zanardo is Director of Sales of Admedus Ltd, formerly Allied Healthcare Group Ltd. He has over 20 years experience in the Australian healthcare sector via positions with multinational pharmaceutical companies, biopharmaceutical startup, and medical device companies. He has gained formal qualifications via a degree in applied science and has built upon this with post graduate business studies, and is currently working towards completing his MBA. During his career, he has developed networks and an intimate understanding of medical device and pharmaceutical commercial and clinical environments. He has a track record of sales, marketing and clinical teams in commercial projects, with new and existing medical technology, that have resulted in revenue growth. Danny has worked with Rousell Uclaf, Hoffman La Roche, and Actelion. He joined Allied Medical as a Regional Sales Manager in 2004 and became National Sales Manager in 2005.
Professional Marks | MBA |
Phone | 61 13 0055 0310 |
Web | https://www.anteristech.com |
Anteris Technologies Management Efficiency
The company has return on total asset (ROA) of (0.8433) % which means that it has lost $0.8433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.5517) %, meaning that it generated substantial loss on money invested by shareholders. Anteris Technologies' management efficiency ratios could be used to measure how well Anteris Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 2 records | EXECUTIVE Age | ||
Kevin Williamson | Tenon Medical | 39 | |
Deina Walsh | Bone Biologics Corp | 60 |
Management Performance
Return On Equity | -2.55 | |||
Return On Asset | -0.84 |
Anteris Technologies Leadership Team
Elected by the shareholders, the Anteris Technologies' board of directors comprises two types of representatives: Anteris Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anteris. The board's role is to monitor Anteris Technologies' management team and ensure that shareholders' interests are well served. Anteris Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anteris Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
AC FAA, Exec | ||
Wayne Paterson, Non-Executive Independent Director | ||
Matthew McDonnell, Chief Officer | ||
David Denis, Chief Officer | ||
Stephen Denaro, Independent Sec | ||
Chris Olig, Bus Director | ||
Danny Zanardo, Commercial International | ||
MPH MD, Chief Board |
Anteris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Anteris Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -2.55 | |||
Return On Asset | -0.84 | |||
Operating Margin | (5.05) % | |||
Current Valuation | 196.49 M | |||
Shares Outstanding | 13.9 M | |||
Shares Owned By Insiders | 13.27 % | |||
Shares Owned By Institutions | 28.34 % | |||
Price To Earning | (3.20) X | |||
Price To Book | 10.09 X | |||
Price To Sales | 30.51 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Anteris Pink Sheet
Anteris Technologies financial ratios help investors to determine whether Anteris Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Anteris with respect to the benefits of owning Anteris Technologies security.